Literature DB >> 16499828

Rational multidrug therapy in the treatment of neuropathic pain.

Misha-Miroslav Backonja1, Gordon Irving, Charles Argoff.   

Abstract

Multidrug therapy (MDT) has been widely accepted and used as a standard of practice in most areas of medical practice, including neuropathic pain. Because neuropathic pain is a new field of medical science and practice, standards for its treatment including MDT are still evolving. In this article, we present rationale and principals for the MDT of neuropathic pain based on our best understandings of the underlying mechanisms of the disease processes and the actions of drugs, the goal being to maximize benefits and minimize adverse effects. MDT for neuropathic pain is based on a comprehensive clinical neuropathic pain assessment and ongoing monitoring of the drug therapy's efficacy and adverse effects, administering one drug at the time.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16499828     DOI: 10.1007/s11916-006-0007-1

Source DB:  PubMed          Journal:  Curr Pain Headache Rep        ISSN: 1534-3081


  24 in total

Review 1.  Pregabalin: in the treatment of postherpetic neuralgia.

Authors:  James E Frampton; Rachel H Foster
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  Morphine, gabapentin, or their combination for neuropathic pain.

Authors:  Ian Gilron; Joan M Bailey; Dongsheng Tu; Ronald R Holden; Donald F Weaver; Robyn L Houlden
Journal:  N Engl J Med       Date:  2005-03-31       Impact factor: 91.245

Review 3.  Pharmacologic treatment of pain in polyneuropathy.

Authors:  S H Sindrup; T S Jensen
Journal:  Neurology       Date:  2000-10-10       Impact factor: 9.910

Review 4.  CLINICAL REVIEW: Use of antiepileptic drugs in the treatment of chronic painful diabetic neuropathy.

Authors:  Aaron Vinik
Journal:  J Clin Endocrinol Metab       Date:  2005-05-17       Impact factor: 5.958

Review 5.  Antidepressants in the treatment of neuropathic pain.

Authors:  Søren H Sindrup; Marit Otto; Nanna B Finnerup; Troels S Jensen
Journal:  Basic Clin Pharmacol Toxicol       Date:  2005-06       Impact factor: 4.080

Review 6.  Individual responder analyses for pain: does one pain scale fit all?

Authors:  Raymond A Dionne; Linda Bartoshuk; Jeffrey Mogil; James Witter
Journal:  Trends Pharmacol Sci       Date:  2005-03       Impact factor: 14.819

7.  Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial.

Authors:  Rainer Sabatowski; Rafael Gálvez; David A Cherry; Florence Jacquot; Emmanuelle Vincent; Pascal Maisonobe; Mark Versavel
Journal:  Pain       Date:  2004-05       Impact factor: 6.961

8.  Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study.

Authors:  Michael C Rowbotham; Veeraindar Goli; Nadia R Kunz; Dean Lei
Journal:  Pain       Date:  2004-08       Impact factor: 6.961

9.  Lidocaine patch 5% with systemic analgesics such as gabapentin: a rational polypharmacy approach for the treatment of chronic pain.

Authors:  William T White; Nileshkumar Patel; Michael Drass; Srinivas Nalamachu
Journal:  Pain Med       Date:  2003-12       Impact factor: 3.750

10.  Painful and non-painful neuropathy in HIV-infected patients: an analysis of somatosensory nerve function.

Authors:  Claes Martin; Göran Solders; Anders Sönnerborg; Per Hansson
Journal:  Eur J Pain       Date:  2003       Impact factor: 3.931

View more
  23 in total

Review 1.  Descending pain modulation and chronification of pain.

Authors:  Michael H Ossipov; Kozo Morimura; Frank Porreca
Journal:  Curr Opin Support Palliat Care       Date:  2014-06       Impact factor: 2.302

2.  Novel insights on diagnosis, cause and treatment of diabetic neuropathy: focus on painful diabetic neuropathy.

Authors:  Mitra Tavakoli; Omar Asghar; Uazman Alam; Ioannis N Petropoulos; Hassan Fadavi; Rayaz A Malik
Journal:  Ther Adv Endocrinol Metab       Date:  2010-04       Impact factor: 3.565

Review 3.  Positive emotions and brain reward circuits in chronic pain.

Authors:  Edita Navratilova; Kozo Morimura; Jennifer Y Xie; Christopher W Atcherley; Michael H Ossipov; Frank Porreca
Journal:  J Comp Neurol       Date:  2016-02-03       Impact factor: 3.215

4.  Population pharmacokinetic model of the pregabalin-sildenafil interaction in rats: application of simulation to preclinical PK-PD study design.

Authors:  Gregor Bender; James Gosset; Jeff Florian; Keith Tan; Mark Field; Scott Marshall; Joost DeJongh; Robert Bies; Meindert Danhof
Journal:  Pharm Res       Date:  2009-08-11       Impact factor: 4.200

Review 5.  Combination drug therapy for chronic pain: a call for more clinical studies.

Authors:  Jianren Mao; Michael S Gold; Miroslav Misha Backonja
Journal:  J Pain       Date:  2010-09-17       Impact factor: 5.820

6.  Effect of duration of postherpetic neuralgia on efficacy analyses in a multicenter, randomized, controlled study of NGX-4010, an 8% capsaicin patch evaluated for the treatment of postherpetic neuralgia.

Authors:  Lynn R Webster; Marvin Tark; Richard Rauck; Jeffrey K Tobias; Geertrui F Vanhove
Journal:  BMC Neurol       Date:  2010-10-11       Impact factor: 2.474

Review 7.  Is migraine a neuropathic pain syndrome?

Authors:  David M Biondi
Journal:  Curr Pain Headache Rep       Date:  2006-06

Review 8.  Pathogenesis of pain in peripheral diabetic neuropathy.

Authors:  Nigel A Calcutt; Miroslav Misha Backonja
Journal:  Curr Diab Rep       Date:  2007-12       Impact factor: 4.810

Review 9.  What is new in neuropathic pain?

Authors:  Mellar P Davis
Journal:  Support Care Cancer       Date:  2006-11-28       Impact factor: 3.359

10.  Screening and Identification of Key Genes, Pathways, and Drugs Associated with Neuropathic Pain in Dorsal Horn: Evidence from Bioinformatic Analysis.

Authors:  Xiao Yang; Lin Zhu; Bingcheng Zhao; Jingjuan Hu; Fan Deng; Shaohui Lei; Zhi-Wen Yao; Kexuan Liu
Journal:  J Pain Res       Date:  2021-06-16       Impact factor: 3.133

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.